Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 2,286 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Open Label Extension Clear all
Recruiting Phase 1Phase 2 Interventional

A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS)

NCT07855211
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIIB147, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
2
States / cities
St Louis, Missouri • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 10:57 AM EDT
Suspended Not applicable Interventional

Compassionate-Use of 4% T-EDTA Lock Solution for Central Venous Lines of Pediatric PN Patients

NCT04559334
View directory record Official record
Conditions
Central Line Complication, Central Line-associated Bloodstream Infection (CLABSI)
Interventions
Tetrasodium EDTA Catheter Lock Solution
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Months to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 25, 2026, 10:57 AM EDT
Completed Phase 2 Interventional

Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase

NCT01602393
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CHF 5074 1x, CHF 5074 2x, CHF 5074 3x
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 79 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Eatontown, New Jersey • Monroe Twp, New Jersey • Toms River, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 25, 2026, 10:57 AM EDT
Completed Phase 4 Interventional

Determine The Percentage Of Depressed Outpatients Who Do Not Effectively Metabolize Extended-release Venlafaxine HCl

NCT00788944
View directory record Official record
Conditions
Depression
Interventions
blood draw
Procedure
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
971 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
52
States / cities
Birmingham, Alabama • Tuscon, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2011 · Synced Oct 25, 2026, 10:57 AM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

NCT03781414
View directory record Official record
Conditions
Liver Transplant Rejection
Interventions
CFZ533, Tacrolimus - MMF - corticosteroids
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 25, 2026, 10:57 AM EDT
Completed Phase 4 Interventional Results available

Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia

NCT00607919
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Dyslexia
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 16 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
16
States / cities
Irvine, California • Palo Alto, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 25, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial

NCT00649792
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
38
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Berkeley, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 25, 2026, 10:57 AM EDT
Completed Phase 1Phase 2 Interventional

Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome

NCT02034071
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
DCCR, Placebo
Drug
Lead sponsor
Essentialis, Inc.
Industry
Eligibility
10 Years to 22 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 25, 2026, 10:57 AM EDT
Recruiting Early Phase 1 Interventional

Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders

NCT05649098
View directory record Official record
Conditions
Skin Diseases
Interventions
Dupilumab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
6 Months and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 25, 2026, 10:57 AM EDT
Completed Phase 4 Interventional Results available

Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)

NCT01462565
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
current marketed FLOLAN (epoprostenol sodium), new thermo stable formulation of epoprostenol sodium
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Miami Beach, Florida • Chicago, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 25, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Results available

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

NCT02782104
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine Nasal Spray
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
51
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 25, 2026, 10:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects

NCT03660800
View directory record Official record
Conditions
Vitamin D Insufficiency, Secondary Hyperparathyroidism
Interventions
CTAP101 Capsules
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 25, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris

NCT02682264
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CB-03-01 cream, 1%
Drug
Lead sponsor
Cassiopea SpA
Industry
Eligibility
9 Years and older
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
39
States / cities
Fort Smith, Arkansas • Little Rock, Arkansas • Sacramento, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 25, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults

NCT01753193
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Anifrolumab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 68 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • La Palma, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 25, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Results available

A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

NCT01067105
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
ciclesonide HFA 160 μg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
824 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
44
States / cities
Huntington Beach, California • Los Angeles, California • Mission Viejo, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Oct 25, 2026, 10:57 AM EDT
Recruiting Phase 3 Interventional

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

NCT06747949
View directory record Official record
Conditions
Sjögren's Syndrome
Interventions
Dazodalibep
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
31
States / cities
Avondale, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 25, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

NCT03828747
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Semorinemab, Placebo, [18F]GTP1
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
31
States / cities
Garden Grove, California • Los Alamitos, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 25, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

NCT00853047
View directory record Official record
Conditions
Carcinoid Syndrome
Interventions
Telotristat etiprate, Octreotide LAR Depot, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
9
States / cities
Little Rock, Arkansas • San Francisco, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 25, 2026, 10:57 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)

NCT06716606
View directory record Official record
Conditions
Connective Tissue Diseases
Interventions
Belimumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 25, 2026, 10:57 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

NCT06290128
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
Interventions
Riliprubart, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
28
States / cities
Homewood, Alabama • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 25, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Results available

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)

NCT01636687
View directory record Official record
Conditions
Plaque-type Psoriasis
Interventions
Placebo, Secukinumab 150mg, Secukinumab 300mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Oceanside, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 25, 2026, 10:57 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

NCT06930625
View directory record Official record
Conditions
Acromegaly
Interventions
Debio 4126, Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 25, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Research Study Investigating Mim8 in People With Haemophilia A

NCT04204408
View directory record Official record
Conditions
Healthy Volunteers, Haemophilia A With or Without Inhibitors
Interventions
NNC0365-3769 (Mim8), Placebo (Mim8)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 25, 2026, 10:57 AM EDT
Suspended Phase 2Phase 3 Interventional

Rollover Extension Clinical Trial To Evaluate The Long-Term Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With CKD IV Completing The US-APR2020-01 Study

NCT05407389
View directory record Official record
Conditions
Chronic Kidney Disease stage4
Interventions
KT-301 (formerly US-APR2020)
Drug
Lead sponsor
Kibow Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Silver Spring, Maryland • Saginaw, Michigan • Orangeburg, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 25, 2026, 10:57 AM EDT